Gyre Therapeutics (GYRE) Long-Term Deferred Tax (2022 - 2026)

Gyre Therapeutics (GYRE) has 5 years of Long-Term Deferred Tax data on file, last reported at $7.7 million in Q1 2026.

• Quarterly Long-Term Deferred Tax rose 32.74% year-over-year to $7.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.7 million (up 32.74% YoY) and the FY2025 annual result came in at $6.9 million, up 22.32% from the prior year.
• Long-Term Deferred Tax climbed to $7.7 million in Q1 2026 per GYRE's latest filing, from $6.9 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $7.7 million in Q1 2026 and bottomed at $4.1 million in Q4 2022.
• The 5-year median for Long-Term Deferred Tax is $5.6 million (2024), against an average of $5.7 million.
• The widest annual swing landed in 2023, when Long-Term Deferred Tax gained 15.05%; it then soared 32.74% in 2026.
• Tracing GYRE's Long-Term Deferred Tax over 5 years: stood at $4.1 million in 2022, then climbed by 15.05% to $4.7 million in 2023, then rose by 19.68% to $5.6 million in 2024, then rose by 22.32% to $6.9 million in 2025, then climbed by 12.37% to $7.7 million in 2026.
• Per Business Quant, the three latest GYRE Long-Term Deferred Tax figures stand at $7.7 million (Q1 2026), $6.9 million (Q4 2025), and $6.7 million (Q3 2025).

Peer Comparison